Physician profile
James Russell
NPI 1285165969
$52,497.04
in general payments reported to CMS, 2019-2025
29 companies · $5,863 in 2025
The $5,863 reported for 2025 was more than what a typical Clinical Cardiac Electrophysiology provider received nationally (typical 2025 total: $2,477).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $659 · 2020: $451 · 2021: $797 · 2022: $1,902 · 2023: $21K · 2024: $22K · 2025: $5,863.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $37K · Food and Beverage: $6,658 · Travel and Lodging: $4,427 · Education: $353.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $37,250.00 |
| Food and Beverage | $6,658.19 |
| Travel and Lodging | $4,426.85 |
| Education | $353.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $20,997.38 | 2019-2025 | Ensite, Aveir, Mitraclip |
| Medtronic, INC. | $16,485.38 | 2022-2025 | Cobalt Dr Mri Surescan, Micra, Selectsecure |
| Boston Scientific Corporation | $8,048.56 | 2019-2025 | General - Therapies, Resonate El Icd Vr, General - Crm_crm |
| Biotronik INC. | $4,448.61 | 2021-2025 | Amvia Edge, Pamira, Selectra |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $353.07 | 2019-2024 | Lifevest |
| Abiomed | $295.93 | 2020-2023 | Impella |
| Novartis Pharmaceuticals Corporation | $283.76 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $264.02 | 2019-2024 | Xarelto |
| Philips North America LLC | $173.26 | 2022-2025 | (Ao0) Igt Devices Intracardiac, Mechanical Tools |
| Biosense Webster, INC. | $130.24 | 2022-2024 | Carto 3 |
| Terumo Medical Corporation | $126.46 | 2022-2023 | Optitorque, Angio-Seal |
| Becton, Dickinson and Company | $118.01 | 2024-2025 | Hemosphere |
| Zoll Circulation INC | $103.00 | 2022 | |
| Edwards Lifesciences Corporation | $92.69 | 2024-2025 | Hemosphere |
| Atricure, INC. | $77.25 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cardiva Medical, INC. | $63.47 | 2023-2025 | Cardiva Vascade Mvp Vvcs 6-12f, Cardiva Vascade 6/7f Vcs |
| Alnylam Pharmaceuticals INC. | $59.96 | 2025 | Onpattro |
| Shockwave Medical, INC | $57.23 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Teleflex LLC | $46.86 | 2022-2025 | Guideliner |
| Impulse Dynamics (USA) INC. | $39.28 | 2023 | Optimizer |
| Asahi Intecc USA, INC. | $37.76 | 2022 | |
| Cordis US Corp. | $30.57 | 2022-2025 | Mynx Control Venous |
| Heartflow, INC. | $28.54 | 2023 | Ffrct |
| Bridgebio Pharma, INC. | $27.23 | 2025 | Attruby |
| Merck Sharp & Dohme LLC | $24.04 | 2023 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.58 | 2024 | Jardiance |
| Actelion Pharmaceuticals US, INC. | $21.94 | 2024 | Uptravi |
| Pfizer INC. | $21.65 | 2025 | |
| Scpharmaceuticals INC. | $17.31 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Russell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.